IO IONS Ionis Pharmaceuticals, Inc. Common Stock Loading... : Bullish and Bearish Analyst Opinions

The author makes a nostalgic reference to Ionis Pharmaceuticals as a past "terror cell" without expressing any current position or trade idea.

Premarket movers report shows mixed Mag 7 stocks, with notable gains for CECO on JPMorgan initiation, ALNY and BBIO on rival drug trial failure, and SMPL on earnings beat, while IBM, IONS, LEVI, MAT, and CRM decline on various negative catalysts.

The tweet reports a list of stocks receiving analyst upgrades but does not state the author's own position, making it a factual research summary rather than a trade idea.

Jeffrey mentions that for his son's disease (CTD), pharmaceutical companies are looking at "ASO therapy" (Antisense Oligonucleotide) and "prodrugs" to bypass the blood-brain barrier. Ionis (IONS) is the market leader in RNA-targeted ASO therapies, and Ultragenyx (RARE) specializes in rare genetic diseases and metabolic disorders. When a specific modality like ASO is highlighted as the solution for neurological transport issues, it validates the broader technology platforms of these specialized firms. Watch these tickers as proxies for advancements in ASO and rare disease drug delivery. Clinical trial failures are common in rare disease; "science is slow" (as stated by the guest).